Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel, Pembrolizumab, and Olaparib in ICI-experienced Gastric and GEJ Cancer
NCT04592211Phase 2Recruiting
- Sponsor
- Yonsei University
- Start
- Oct 2021
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib, pembrolizumab in gastric cancer (GC), gastroesophageal junction cancer, sponsored by Yonsei University. Started Oct 2021; status: recruiting.
02
Drugs
olaparibpembrolizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT04592211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04592211.